跳轉至內容
Merck
全部照片(1)

Key Documents

Y0001642

卡培他滨

European Pharmacopoeia (EP) Reference Standard

同義詞:

5′-脱氧-5-氟-N-[(戊氧基)羰基]胞苷, Ro-9-1978

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C15H22FN3O6
CAS號碼:
分子量::
359.35
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

capecitabine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

O[C@H]1[C@@H](O)[C@H](N2C(N=C(NC(OCCCCC)=O)C(F)=C2)=O)O[C@@H]1C

InChI

1S/C15H22FN3O6/c1-3-4-5-6-24-15(23)18-12-9(16)7-19(14(22)17-12)13-11(21)10(20)8(2)25-13/h7-8,10-11,13,20-21H,3-6H2,1-2H3,(H,17,18,22,23)/t8-,10-,11-,13-/m1/s1

InChI 密鑰

GAGWJHPBXLXJQN-UORFTKCHSA-N

基因資訊

human ... TYMS(7298)

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Capecitabine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

卡培他滨是一种抗癌药物,是去氧氟尿苷的前药,在肿瘤部位代谢为5-氟尿嘧啶。 卡培他滨的激活遵循具有三个酶促步骤和两个中间代谢物5′-脱氧-5-氟胞苷(5′-DFCR)和5′-脱氧-5-氟尿苷(5′-DFUR)的途径,形成5-氟尿嘧啶。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Health hazard

訊號詞

Danger

危險聲明

防範說明

危險分類

Carc. 1B - Muta. 2 - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Francesco Giotta et al.
Tumori, 99(6), 278e-281e (2014-02-08)
We present the case of a 58-year-old woman with breast cancer metastasizing to the liver after adjuvant chemotherapy. A liver biopsy confirmed metastatic lesions from breast cancer that were immunohistochemically positive for estrogen/progesterone receptors and HER2. After first-line treatment with
Karen-Lise G Spindler et al.
Anticancer research, 34(2), 845-850 (2014-02-11)
We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement. Patients' inclusion criteria included histopathologically-verified mCRC refractory to standard chemotherapy, adequate
Dermatomyositis associated with capecitabine in the setting of malignancy.
Frank W Chen et al.
Journal of the American Academy of Dermatology, 70(2), e47-e48 (2014-01-21)
Mitsuhiro Tomoda et al.
Anticancer research, 34(1), 191-194 (2014-01-10)
Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy. In the present study, we administered monthly chemotherapy and aimed to evaluate the usefulness of the specific treatment schedule in patients with
Tim Meyer et al.
European journal of cancer (Oxford, England : 1990), 50(5), 902-911 (2014-01-22)
Cytotoxic chemotherapy is widely used for advanced, unresectable pancreatic and other gastrointestinal foregut neuroendocrine tumours (NETs) and the most commonly used regimen combines 5-fluorouracil with streptozocin. The NET01 trial was designed to investigate whether capecitabine combined with streptozocin was an

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務